Summary
Global Markets Direct’s, ‘Chagas Disease (American Trypanosomiasis) - Pipeline Review, H1 2016’, provides an overview of the Chagas Disease (American Trypanosomiasis) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Chagas Disease (American Trypanosomiasis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chagas Disease (American Trypanosomiasis) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Chagas Disease (American Trypanosomiasis)
- The report reviews pipeline therapeutics for Chagas Disease (American Trypanosomiasis) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Chagas Disease (American Trypanosomiasis) therapeutics and enlists all their major and minor projects
- The report assesses Chagas Disease (American Trypanosomiasis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Chagas Disease (American Trypanosomiasis)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Chagas Disease (American Trypanosomiasis)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chagas Disease (American Trypanosomiasis) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Anacor Pharmaceuticals, Inc.
Bayer AG
Eisai Co., Ltd.
GlaxoSmithKline Plc
Grupo Praxis Pharmaceutical SA
KaloBios Pharmaceuticals, Inc.
Merck & Co., Inc.
Panacela Labs, Inc.
Sanofi
SEEK Group
'
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Chagas Disease (American Trypanosomiasis) Overview 10
Therapeutics Development 11
Pipeline Products for Chagas Disease (American Trypanosomiasis) – Overview 11
Pipeline Products for Chagas Disease (American Trypanosomiasis) – Comparative Analysis 12
Chagas Disease (American Trypanosomiasis) – Therapeutics under Development by Companies 13
Chagas Disease (American Trypanosomiasis) – Therapeutics under Investigation by Universities/Institutes 14
Chagas Disease (American Trypanosomiasis) – Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Chagas Disease (American Trypanosomiasis) – Products under Development by Companies 18
Chagas Disease (American Trypanosomiasis) – Products under Investigation by Universities/Institutes 19
Chagas Disease (American Trypanosomiasis) – Companies Involved in Therapeutics Development 21
Anacor Pharmaceuticals, Inc. 21
Bayer AG 22
Eisai Co., Ltd. 23
GlaxoSmithKline Plc 24
Grupo Praxis Pharmaceutical SA 25
KaloBios Pharmaceuticals, Inc. 26
Merck & Co., Inc. 27
Panacela Labs, Inc. 28
Sanofi 29
SEEK Group 30
Chagas Disease (American Trypanosomiasis) – Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
benznidazol - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
benznidazole - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
chagas disease (bivalent) vaccine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
chagas disease vaccine - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
chagas disease vaccine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
chagas disease vaccine - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Chagas disease vaccine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Cz-007 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Cz-008 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
EPLBS-1246 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
EPLBS-967 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
fexinidazole - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
fosravuconazole - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
K-777 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Monoclonal Antibody for Chagas - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
NEU-321 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
nifurtimox - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
nifurtimox SR - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
posaconazole - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Small Molecule to Inhibit Cruzipain for Chagas Disease - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Small Molecule to Inhibit SOD for Chagas Disease and Leishmaniasis - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Small Molecules for Chagas Disease - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Small Molecules for Chagas Disease - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Small Molecules for Chagas Disease - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Small Molecules for Chagas Disease - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Small Molecules for Chagas Disease - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Small Molecules for Chagas Disease - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Small Molecules for Infectious Diseases - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Small Molecules for Infectious Diseases - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Small Molecules for Protozoal Infections - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for Chagas Disease - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Small Molecules to Inhibit Proline Racemase for Chagas Disease - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
VNI - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
XELRYX-3 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Chagas Disease (American Trypanosomiasis) – Recent Pipeline Updates 80
Chagas Disease (American Trypanosomiasis) - Dormant Projects 83
Chagas Disease (American Trypanosomiasis) – Discontinued Products 84
Chagas Disease (American Trypanosomiasis) – Product Development Milestones 85
Featured News & Press Releases 85
May 07, 2015: UTMB researchers devise vaccine that provides long-term protection against Chagas disease 85
Dec 26, 2013: New Drug Candidates Show Promise for Cure for Chagas Disease 86
Nov 14, 2013: Drug Trial for Leading Parasitic Killer of the Americas Shows Mixed Results but Provides New Evidence for Improved Therapy 86
May 03, 2013: Funding boost for GSK’s open innovation research into diseases affecting the developing world 88
Apr 30, 2012: NYU School of Medicine Receives Support From The Tres Cantos Open Lab Foundation To Discover New Drugs Against Chagas Disease 89
Mar 12, 2012: DNDi Receives €2m Strategic Translation Award From Wellcome Trust To Develop New Drug Against Chagas Disease 89
Appendix 91
Methodology 91
Coverage 91
Secondary Research 91
Primary Research 91
Expert Panel Validation 91
Contact Us 91
Disclaimer 92
List of Tables
Number of Products under Development for Chagas Disease (American Trypanosomiasis), H1 2016 11
Number of Products under Development for Chagas Disease (American Trypanosomiasis) – Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 14
Comparative Analysis by Late Stage Development, H1 2016 15
Comparative Analysis by Clinical Stage Development, H1 2016 16
Comparative Analysis by Early Stage Development, H1 2016 17
Products under Development by Companies, H1 2016 18
Products under Investigation by Universities/Institutes, H1 2016 19
Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 20
Chagas Disease (American Trypanosomiasis) – Pipeline by Anacor Pharmaceuticals, Inc., H1 2016 21
Chagas Disease (American Trypanosomiasis) – Pipeline by Bayer AG, H1 2016 22
Chagas Disease (American Trypanosomiasis) – Pipeline by Eisai Co., Ltd., H1 2016 23
Chagas Disease (American Trypanosomiasis) – Pipeline by GlaxoSmithKline Plc, H1 2016 24
Chagas Disease (American Trypanosomiasis) – Pipeline by Grupo Praxis Pharmaceutical SA, H1 2016 25
Chagas Disease (American Trypanosomiasis) – Pipeline by KaloBios Pharmaceuticals, Inc., H1 2016 26
Chagas Disease (American Trypanosomiasis) – Pipeline by Merck & Co., Inc., H1 2016 27
Chagas Disease (American Trypanosomiasis) – Pipeline by Panacela Labs, Inc., H1 2016 28
Chagas Disease (American Trypanosomiasis) – Pipeline by Sanofi, H1 2016 29
Chagas Disease (American Trypanosomiasis) – Pipeline by SEEK Group, H1 2016 30
Assessment by Monotherapy Products, H1 2016 31
Number of Products by Stage and Target, H1 2016 33
Number of Products by Stage and Mechanism of Action, H1 2016 35
Number of Products by Stage and Route of Administration, H1 2016 37
Number of Products by Stage and Molecule Type, H1 2016 39
Chagas Disease (American Trypanosomiasis) Therapeutics – Recent Pipeline Updates, H1 2016 80
Chagas Disease (American Trypanosomiasis) – Dormant Projects, H1 2016 83
Chagas Disease (American Trypanosomiasis) – Discontinued Products, H1 2016 84
List of Figures
Number of Products under Development for Chagas Disease (American Trypanosomiasis), H1 2016 11
Number of Products under Development for Chagas Disease (American Trypanosomiasis) – Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 14
Comparative Analysis by Early Stage Products, H1 2016 17
Assessment by Monotherapy Products, H1 2016 31
Number of Products by Targets, H1 2016 32
Number of Products by Stage and Targets, H1 2016 32
Number of Products by Mechanism of Actions, H1 2016 34
Number of Products by Stage and Mechanism of Actions, H1 2016 34
Number of Products by Routes of Administration, H1 2016 36
Number of Products by Stage and Routes of Administration, H1 2016 36
Number of Products by Molecule Types, H1 2016 38
Number of Products by Stage and Molecule Types, H1 2016 38
